<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB05C424-91BF-4B48-9472-E6F6226A6A05"><gtr:id>CB05C424-91BF-4B48-9472-E6F6226A6A05</gtr:id><gtr:name>University of London</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Malet Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 7HU</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9"><gtr:id>ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9</gtr:id><gtr:name>Curie Institute Paris (Institut Curie)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>Lymphocyte Signalling and Development</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB05C424-91BF-4B48-9472-E6F6226A6A05"><gtr:id>CB05C424-91BF-4B48-9472-E6F6226A6A05</gtr:id><gtr:name>University of London</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Malet Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 7HU</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9"><gtr:id>ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9</gtr:id><gtr:name>Curie Institute Paris (Institut Curie)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/75E77BF3-29B4-4699-9CD9-223230E8A463"><gtr:id>75E77BF3-29B4-4699-9CD9-223230E8A463</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/62BD448E-C35F-4E65-A090-014918671BEC"><gtr:id>62BD448E-C35F-4E65-A090-014918671BEC</gtr:id><gtr:firstName>Francesco</gtr:firstName><gtr:surname>Colucci</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501150"><gtr:id>7CF169DC-2D08-403E-A71F-E95A2E78A239</gtr:id><gtr:title>Natural cellular cytotoxicity in tumour surveillance and immunity to infections</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501150</gtr:grantReference><gtr:abstractText>We try to find out how white blood cells called natural killer (NK) cells fight microbes and tumours. 
We know that NK cells have a natural tendency to kill infected and tumour cells in the test tube, however it is difficult to study these mechanisms in the human body. So we use mice in our research, because their immune defences are well defined and fairly similar to ours. 
By modelling human diseases in laboratory mice, we are gaining important insights into how to harness the potential of our natural resources to fight infections and cancer. 
For example, we have identified a single gene that regulates the killer cell?s action and protects against viral infections and blood-born cancer. We are now trying to discover how NK cells attack a type of skin cancer known as melanoma. 
By learning more about how our natural defences work, we will be able to think of more effective cures against infection and cancer.</gtr:abstractText><gtr:technicalSummary>We propose a new and unique mouse model of NK cell-selective deficient cytotoxicity. This model is based on the first Natural Killer (NK)-specific knock-out mouse, which expresses an inactive form of phospholipase C-gamma2. PLCg2 is a key regulator of natural cytotoxicity but not acquired cytotoxicity. Thus, NK cells will be faulty whereas cytotoxic T lymphocytes (CTL) responses will be intact. By challenging these mice with mouse cytomegalovirus and Listeria monocytogenes, we will be able to address the question of how innate immunity shapes the outcome of adaptive T cell responses to infectious pathogens. We will also be able to uncouple NK and CTL cytotoxicity in the contraction phase of lymphocyte responses. By crossing this mouse with a mouse model of spontaneous melanoma we will have the unique opportunity of appreciating the impact of natural cytotoxicity on primary tumours.</gtr:technicalSummary><gtr:fund><gtr:end>2009-07-18</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-07-19</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>312247</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cancer Research UK (ICR)</gtr:department><gtr:description>Immune recognition of melanoma</gtr:description><gtr:id>099BC962-85CD-49AA-81A2-647F657C5C31</gtr:id><gtr:impact>Publication 19349689</gtr:impact><gtr:partnerContribution>Provided insights and clinical materialProvided transgenic miceProvided insights, reagents and expertise in cell signallingProvided transgenic mice Provided transgenic mice</gtr:partnerContribution><gtr:piContribution>Melanoma recognition by NK cell receptors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Babraham Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Immune recognition of melanoma</gtr:description><gtr:id>C7FFC122-4684-44E4-9925-2584309AE1C2</gtr:id><gtr:impact>Publication 19349689</gtr:impact><gtr:partnerContribution>Provided insights and clinical materialProvided transgenic miceProvided insights, reagents and expertise in cell signallingProvided transgenic mice Provided transgenic mice</gtr:partnerContribution><gtr:piContribution>Melanoma recognition by NK cell receptors</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Immune recognition of melanoma</gtr:description><gtr:id>AF597CF9-846C-4B22-BF89-F597C529A2E5</gtr:id><gtr:impact>Publication 19349689</gtr:impact><gtr:partnerContribution>Provided insights and clinical materialProvided transgenic miceProvided insights, reagents and expertise in cell signallingProvided transgenic mice Provided transgenic mice</gtr:partnerContribution><gtr:piContribution>Melanoma recognition by NK cell receptors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Curie Institute Paris (Institut Curie)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Claudius Regaud Hospital</gtr:department><gtr:description>Immune recognition of melanoma</gtr:description><gtr:id>9E921680-5C1A-4CEC-899D-267EDC0FACD4</gtr:id><gtr:impact>Publication 19349689</gtr:impact><gtr:partnerContribution>Provided insights and clinical materialProvided transgenic miceProvided insights, reagents and expertise in cell signallingProvided transgenic mice Provided transgenic mice</gtr:partnerContribution><gtr:piContribution>Melanoma recognition by NK cell receptors</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ulm</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Immune recognition of melanoma</gtr:description><gtr:id>16D3BA40-62E4-411B-B95E-D541D7EFA284</gtr:id><gtr:impact>Publication 19349689</gtr:impact><gtr:partnerContribution>Provided insights and clinical materialProvided transgenic miceProvided insights, reagents and expertise in cell signallingProvided transgenic mice Provided transgenic mice</gtr:partnerContribution><gtr:piContribution>Melanoma recognition by NK cell receptors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media coverage</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>04FBC07E-5967-4CAC-A0D8-9CEBCF50508B</gtr:id><gtr:impact>The work done under this MRC grant was highlighted on the Babraham website as &amp;quot;paper of the month&amp;quot; in May 2009 and received media coverage, including an article in the Cambridge Evening News and BBSRC Business Magazine in January 2009.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>20479037-96A7-4B02-B30D-EB4E656FC079</gtr:id><gtr:impact>We have published an article in &amp;quot;The Naked Scientist&amp;quot; and a student assay was shortlisted among the top 10 for the MRC Max Perutz Science writing competition 2007.

Public awareness of science</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits - Cambridge</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>B583B61C-9FEC-4EDC-A4F4-6598E87FBBC2</gtr:id><gtr:impact>Three visits to primary and secondary schools in the Cambridge area and participation to the Cambridge Science Festival in 2007.

School and public awareness of science</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Online seminar</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>63EC4AE9-0639-4A85-9546-FF784B8BE918</gtr:id><gtr:impact>We presented our work in a Henry Stewart online seminar

Henry Stewart online seminars are accessed by a range of universities, medical schools, colleges, manufacturers, government agencies and service companies throughout the world.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>173000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>162D8A73-D3B8-44EE-BFAC-F3E1139E368C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (Modulation of immune responses during haematopoietic cell transplantation)</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>9275F2DB-1759-4F4C-A41D-EB42E02C3A09</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A Simple Method to Measure NK Cell Cytotoxicity In Vivo</gtr:description><gtr:id>3AB00F36-CC8A-4CD2-9844-EDF4294D4267</gtr:id><gtr:impact>Natural cytotoxicity is considered an important parameter used to evaluate NK cell biology, both in the clinic and in the research lab. In this chapter we describe a simple method to quantify spontaneous NK cell cytotoxicity in vivo.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>NK Cell Cytotoxicity</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8203E242-9B40-41DE-9D9D-90D573EB5517"><gtr:id>8203E242-9B40-41DE-9D9D-90D573EB5517</gtr:id><gtr:title>Analysis of uterine natural killer cells in mice.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41c34c4cce22638ec6c0be1901e3d6b2"><gtr:id>41c34c4cce22638ec6c0be1901e3d6b2</gtr:id><gtr:otherNames>Croy BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/545B4348-6D5C-4E20-96A4-960F8C59C933"><gtr:id>545B4348-6D5C-4E20-96A4-960F8C59C933</gtr:id><gtr:title>Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/46346cbf44e848fbe06e531688e1a872"><gtr:id>46346cbf44e848fbe06e531688e1a872</gtr:id><gtr:otherNames>Li P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/514E6364-A59F-4486-941D-8E5C1C953640"><gtr:id>514E6364-A59F-4486-941D-8E5C1C953640</gtr:id><gtr:title>New views on natural killer cell-based immunotherapy for melanoma treatment.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aab5d4a91a13e483f930b29ca0d79602"><gtr:id>aab5d4a91a13e483f930b29ca0d79602</gtr:id><gtr:otherNames>Burke S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFB7EE03-048C-49E9-A85C-166794B0BFD2"><gtr:id>DFB7EE03-048C-49E9-A85C-166794B0BFD2</gtr:id><gtr:title>A simple method to measure NK cell cytotoxicity in vivo.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45ffa0de99c14c1e4c4510e05e864f81"><gtr:id>45ffa0de99c14c1e4c4510e05e864f81</gtr:id><gtr:otherNames>Saudemont A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D987543-430C-460E-B063-F75FFBFC0193"><gtr:id>9D987543-430C-460E-B063-F75FFBFC0193</gtr:id><gtr:title>Unique receptor repertoire in mouse uterine NK cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b82b839b27e018ec5bfe722fbb2a1c59"><gtr:id>b82b839b27e018ec5bfe722fbb2a1c59</gtr:id><gtr:otherNames>Yadi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08722B8A-1901-467D-95B1-66C8FA02C3DE"><gtr:id>08722B8A-1901-467D-95B1-66C8FA02C3DE</gtr:id><gtr:title>NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aea9ca31bfc3f0c865025ec58238a2b0"><gtr:id>aea9ca31bfc3f0c865025ec58238a2b0</gtr:id><gtr:otherNames>Lakshmikanth T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501150</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>12A0B409-0C29-4056-9092-2D86E44017F3</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>1.4  Methodologies and measurements</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>